Referred to the House Committee on Energy and Commerce.
The bill amends FD&C Act section 505(j) to require the HHS Secretary to inform a generic applicant whether its proposed drug is qualitatively and quantitatively the same as the listed drug, and to identify and quantify any differences. It restricts the Secretary’s ability to rescind a sameness determination after an abbreviated new drug application is submitted except for limited safety/error exceptions, requires HHS to issue draft and final guidance within specified timeframes, and makes the new provisions effective upon enactment.
Progressives stress potential safety tradeoffs from constrained FDA flexibility
Technocratic, narrow bill likely gains bipartisan support but may face industry lobbying from brand manufacturers.
The bill amends FD&C Act section 505(j) to require the HHS Secretary to inform a generic applicant whether its proposed drug is qualitatively and quantitatively the same as the listed drug, and to identify and quantify any differences.
It restricts the Secretary’s ability to rescind a sameness determination after an abbreviated new drug application is submitted except for limited safety/error exceptions, requires HHS to issue draft and final guidance within specified timeframes, and makes the new provisions effective upon enactment.
Narrow, non-ideological reform increases prospects, but industry opposition and Senate procedural barriers reduce chances.
How solid the drafting looks.
Progressives stress potential safety tradeoffs from constrained FDA flexibility
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives stress potential safety tradeoffs from constrained FDA flexibility
Likely cautiously supportive because transparency may speed generic competition and lower drug costs.
However, this persona will be concerned that limiting agency flexibility could hinder safety protections and that guidance must guard public health.
Likely supportive overall as a procedural, pro-transparency reform that reduces applicant uncertainty.
This persona will emphasize careful, prompt guidance and balance between predictability and retaining agency safety authority.
Likely supportive because the bill increases transparency, predictability, and limits sudden regulatory reversals that harm market certainty.
Mainstream conservatives will view the change as pro-competition and pro-business.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, non-ideological reform increases prospects, but industry opposition and Senate procedural barriers reduce chances.
The bill has not accumulated any surfaced votes yet.
Progressives stress potential safety tradeoffs from constrained FDA flexibility
Narrow, non-ideological reform increases prospects, but industry opposition and Senate procedural barriers reduce chances.
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for To amend the Federal Food, Drug, and Cosmetic Act to increase…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.